Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002925 | Ciliary Motility Disorders NIH | 0.71 |
| D020820 | Dyskinesias NIH | 0.71 |
| D011014 | Pneumonia NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012164 | Asterixis HPO | 0.71 |
| HP:0012265 | Ciliary dyskinesia HPO | 0.71 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 2 clinical trials
This study project includes a single-arm phase 2 study and a parallel cohort study, enrolling patients with COVID-19 pneumonia.
Description: 2-week lethality is defined as the ratio of the number of subjects dead within 14 days from study start out of phase 2 patients with baseline information.
Measure: Lethality rate two weeks after registration Time: up to 15 daysDescription: 1-month lethality is defined as the ratio of the number of subjects dead within 30 days from study start out of phase 2 patients with baseline information.
Measure: Lethality rate one month after registration Time: up to 1 monthDescription: IL-6 levels will be assessed using commercial ELISA method.
Measure: Interleukin-6 level Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: Lymphocyte count assessed by routinely used determination of blood count
Measure: Lymphocyte count Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: CRP is assessed by routinely used determination of CRP
Measure: CRP (C-reactive protein) level Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: calculated from arterial blood gas analyses (values from 300 to 100)
Measure: PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: It evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.
Measure: Change of the SOFA (Sequential Organ Failure Assessment) Time: baseline, during treatment (cycle 1 and 2 every 12 hours) up to 1 monthDescription: graded according to CTCAE citeria (v5.0)
Measure: Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0 Time: during treatment and up to 30 days after the last treatment doseDescription: Thoracic CT scan or Chest XR
Measure: Radiological response Time: at baseline (optional), after seven days and if clinically indicated (up to 1 month)Description: Days of hospitalization
Measure: Duration of hospitalization Time: from baseline up to patient's discharge (up to 1 month)Description: time to invasive mechanical ventilation (if not previously initiated) calculated from baseline to intubation
Measure: Remission of respiratory symptoms Time: up to 1 monthDescription: time to definitive extubation calculated from intubation (any time occurred) to extubation in days
Measure: Remission of respiratory symptoms Time: up to 1 monthDescription: time to independence from non-invasive mechanical ventilation calculated in days
Measure: Remission of respiratory symptoms Time: up to 1 monthDescription: time to independence from oxygen therapy in days
Measure: Remission of respiratory symptoms Time: up to 1 monthAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)
Measure: the mortality rate Time: 90 dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports